/GH
GH Stock - Guardant Health, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$99.74+2.72%
+$2.64 (+2.72%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).52
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.57
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1.0%upside
Target: $100.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$98.74 – $100.74
TARGET (TP)$100.72
STOP LOSS$91.76
RISK/REWARD1:0.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.59
52W High$112.43
52W Low$29.91
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $739.02M | $563.95M | $449.54M | $373.65M | $286.73M |
| Gross Profit | $449.22M | $336.90M | $293.21M | $250.74M | $194.19M |
| Gross Margin | 60.8% | 59.7% | 65.2% | 67.1% | 67.7% |
| Operating Income | $-443,594,000 | $-564,725,000 | $-544,378,000 | $-411,001,000 | $-254,950,000 |
| Net Income | $-436,373,000 | $-479,449,000 | $-654,588,000 | $-405,670,000 | $-253,783,000 |
| Net Margin | -59.0% | -85.0% | -145.6% | -108.6% | -88.5% |
| EPS | $-3.56 | $-4.28 | $-6.41 | $-3.80 | $-2.53 |
Company Overview
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
13
81%
Hold / Neutral
3
19%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
13 Bullish3 Neutral/Bearish
Price Targets
$59
Average Target
↓ 40.8% Downside
Now
$27
Low
$59
Average
$130
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Overweight | $130 |
| September 25th 2025 | Wolfe Research | Upgrade | Outperform | $75 |
| September 22nd 2025 | Wells Fargo | Resumed | Overweight | $72 |
| April 10th 2025 | Mizuho | Initiation | Outperform | $55 |
| January 23rd 2025 | Barclays | Initiation | Overweight | $60 |
| June 28th 2024 | Guggenheim | Upgrade | Buy | $36 |
| June 3rd 2024 | Jefferies | Resumed | Buy | $32 |
| April 24th 2024 | Craig Hallum | Resumed | Buy | $28 |
| December 14th 2023 | Guggenheim | Initiation | Neutral | - |
| December 13th 2023 | Wolfe Research | Initiation | Peer Perform | - |
| November 13th 2023 | Raymond James | Upgrade | Outperform | $27 |
| September 28th 2023 | Bernstein | Initiation | Outperform | $34 |
| September 27th 2023 | Piper Sandler | Upgrade | Overweight | $40 |
| July 5th 2023 | JP Morgan | Resumed | Overweight | $65 |
| May 26th 2023 | Citigroup | Upgrade | Buy | $40← $28 |
Earnings History & Surprises
GHBeat Rate
67%
Last 18 quarters
Avg Surprise
+1.6%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
-69.9%
$-1.58vs$-0.93
Q2 24
+36.1%
$-0.46vs$-0.72
Q3 24
+15.8%
$-0.48vs$-0.57
Q4 24
+18.2%
$-0.45vs$-0.55
Q1 25
+17.3%
$-0.62vs$-0.75
Q2 25
+19.7%
$-0.49vs$-0.61
Q3 25
+15.4%
$-0.44vs$-0.52
Q4 25
+18.7%
$-0.39vs$-0.48
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.43 | — | — | — |
Q4 2025 | Oct 29, 2025 | $-0.48 | $-0.39 | +18.7% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $-0.52 | $-0.44 | +15.4% | ✓ BEAT |
Q2 2025 | Apr 30, 2025 | $-0.61 | $-0.49 | +19.7% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-0.75 | $-0.62 | +17.3% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.55 | $-0.45 | +18.2% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.57 | $-0.48 | +15.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.72 | $-0.46 | +36.1% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.93 | $-1.58 | -69.9% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.93 | $-0.73 | +21.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.25 | $-0.67 | +46.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-1.26 | $-1.30 | -3.2% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-1.40 | $-1.36 | +2.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.27 | $-1.58 | -24.4% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-1.25 | $-2.25 | -80.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-1.23 | $-1.21 | +1.6% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-1.13 | $-0.89 | +21.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-0.90 | $-1.06 | -17.8% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.87 | $-0.96 | -10.3% | ✗ MISS |
Latest News
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $120
📈 PositiveBenzinga•Dec 17, 2025, 01:00 PM
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $120
📈 PositiveBenzinga•Dec 15, 2025, 08:59 PM•Also:
Leerink Partners Maintains Outperform on Guardant Health, Raises Price Target to $155
📈 PositiveBenzinga•Dec 15, 2025, 08:47 PM
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $120
📈 PositiveBenzinga•Dec 15, 2025, 07:08 PM
Wells Fargo Maintains Overweight on Guardant Health, Raises Price Target to $120
📈 PositiveBenzinga•Dec 15, 2025, 06:19 PM
BTIG Maintains Buy on Guardant Health, Raises Price Target to $140
📈 PositiveBenzinga•Dec 12, 2025, 11:10 AM
Citigroup Maintains Buy on Guardant Health, Raises Price Target to $135
📈 PositiveBenzinga•Dec 11, 2025, 09:08 PM•Also:
Guardant Health And Trial Library Collaborate To Increase Access To Cancer Clinical Trials In US
📈 PositiveBenzinga•Dec 11, 2025, 01:07 PM
Guardant Health To Present Total Of 14 Abstracts With Research Collaborators From Multiple Studies Demonstrating Value Of Tissue-Free Liquid Biopsy Tests At 2025 SABCS
📈 PositiveBenzinga•Dec 5, 2025, 01:12 PM
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $130
📈 PositiveBenzinga•Dec 2, 2025, 05:40 PM
Guardant Health Expands Guardant Reveal Blood Test To Monitor Late-Stage Cancer Therapy Response
📈 PositiveBenzinga•Nov 10, 2025, 01:13 PM
Guardant Health Data From Shield Blood-based Screening Test Shows 95% Patient Adherence For Colorectal Cancer
📈 PositiveBenzinga•Nov 5, 2025, 09:50 PM
Guardant Health shares are trading lower after the company announced a $250 million offering of its common stock and a $300 million offering of convertible senior notes.
📉 NegativeBenzinga•Nov 5, 2025, 11:40 AM
Guardant Health Prices Upsized $350M 0% Convertible Senior Notes Due 2033 In Private Offering
➖ NeutralBenzinga•Nov 5, 2025, 08:37 AM
Guardant Health shares are trading lower after the company announced a $250 million offering of its common stock and a $300 million offering of convertible senior notes.
📉 NegativeBenzinga•Nov 4, 2025, 10:06 PM
Guardant Health Announces Proposed $300M Offering Of Convertible Senior Notes Due 2033
➖ NeutralBenzinga•Nov 4, 2025, 09:42 PM
Guardant Health Announces $250M Underwritten Public Offering Of Its Common Stock
➖ NeutralBenzinga•Nov 4, 2025, 09:41 PM
UBS Maintains Buy on Guardant Health, Raises Price Target to $110
📈 PositiveBenzinga•Oct 30, 2025, 07:15 PM
Citigroup Maintains Buy on Guardant Health, Raises Price Target to $100
📈 PositiveBenzinga•Oct 30, 2025, 06:17 PM•Also:
Evercore ISI Group Maintains Outperform on Guardant Health, Raises Price Target to $90
📈 PositiveBenzinga•Oct 30, 2025, 04:48 PM
Frequently Asked Questions about GH
What is GH's current stock price?
Guardant Health, Inc. (GH) is currently trading at $99.74 per share. The stock has moved +2.72% today.
What is the analyst price target for GH?
The average analyst price target for GH is $100.72, based on 1 analyst.
What sector is Guardant Health, Inc. in?
Guardant Health, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is GH's market cap?
Guardant Health, Inc. has a market capitalization of $12.38 billion, making it a large-cap company.
Does GH pay dividends?
No, Guardant Health, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
EHC
Encompass Health Corporation
$106.39
Mkt Cap: $10.7B
EXAS
Exact Sciences Corporation
$101.82
Mkt Cap: $19.3B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
SOLV
Solventum Corporation
$81.59
Mkt Cap: $14.2B
VTRS
Viatris Inc.
$11.93
Mkt Cap: $13.7B
Explore stocks similar to GH for comparison